Nureca Limited, a leading player in the home healthcare and wellness industry, today announced its financial results for the fourth quarter and year ended March 31, 2025
Key Highlights:
Strong Financial Performance
* Q4 FY25 (Jan-Mar 2025)
* Revenue surged 87% to Rs. 31.74 crore (from Rs. 16.97 crore in Q4 FY24)
* EBIDTA improved 156% to Rs. 3.2 crore (from Rs. -5.6 crore in Q4 FY24)
* Full Year FY25
* Revenue grew 19.3% to Rs. 109.66 crore (from Rs. 91.9 crore in FY24)
* EBIDTA increased 1489% to Rs. 4.9 crore (from Rs. 0.3 crore in FY24)
Regulatory Milestone: USFDA Registration
Nureca Technologies Private Limited, the manufacturing arm of Nureca Limited, has successfully completed its annual registration with the U.S. FDA for its 510(k)-exempt medical devices. This milestone validates the company’s regulatory compliance and strengthens its global export capabilities from its Mohali-based facility.
Channel Expansion: D2C & Quick Commerce
Nureca continues to scale its Direct-to-Consumer (D2C) channel, investing in website UX, digital marketing, influencer engagement, and customer service. The company also expanded its reach through Swiggy instamart, reinforcing its commitment to convenient, on-demand wellness solutions. Our products are already available on quick commerce platforms like Blinkit and Zepto, apart from all leading online marketplaces.
Key Strategic Priorities for FY26
* Manufacturing Expansion: Operationalize and scale production at the Punjab facility to support local and export markets.
* Quick Commerce Leadership: Deepen partnerships, expand product assortment, and optimize fulfillment models for quick commerce platforms.
* Innovation Pipeline: Launch new health, wellness, and fitness SKUs aligned to emerging consumer needs.